Joseph F. Merola, MD, MSc

Associate Professor, Dept Dermatology and Dept of Medicine, Division of Rheumatology at Harvard Medical School
Harvard Medical School, Brigham and Women's Hospital
Newton, MA, United States

Joseph F. Merola, MD, MMSc, is Associate Professor in the Department of Dermatology and Department of Medicine, Division of Rheumatology at Harvard Medical School in Boston, Massachusetts. Dr. Merola is board-certified in Dermatology, Internal Medicine, and Rheumatology. He serves as Vice Chair for Clinical Trials, the Director of the Clinical Unit for Research Innovation and Trials (CUReIT), Director of the Center for Skin and Related Musculoskeletal Diseases and the Associate Program Director for the Harvard Combined Internal Medicine-Dermatology Residency Training Program at Brigham and Women’s Hospital in Boston. He is president of the Psoriasis and Psoriatic Arthritis Multicenter Advancement Network (PPACMAN), executive committee of GRAPPA and NPF medical and scientific board member; he is on the medical and scientific board of the Lupus Foundation of America (LFA) and president elect of the medical dermatology society.

Disclosure information not submitted.

Presentation(s):

• 0308: Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies

  Saturday, November 12, 2022
  1:00 PM – 3:00 PM Eastern Time

• Challenges in Psoriatic Disease: When Skin and Joint Symptoms Are Divergent

  Saturday, November 12, 2022
  4:30 PM – 5:15 PM Eastern Time

• 1599: Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

  Sunday, November 13, 2022
  3:30 PM – 3:40 PM Eastern Time

• 241: Going the Distance in Spondyloarthritis: Case Challenges in Evidence-Based Care

  Monday, November 14, 2022
  7:00 AM – 8:30 AM Eastern Time

• 242: Raising the Bar: Implementing Treatment Goals in Clinical Practice for Inflammatory Joint Diseases

  Monday, November 14, 2022
  7:00 AM – 8:30 AM Eastern Time

• 2125: Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time